Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XKH004 (LZM012) in Active Ankylosing Spondylitis – Phase II
CTR20212135Phase 2Completed
- Sponsor
- Kanova
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of lzm012 in ankylosing spondylitis (AS), sponsored by Kanova. Started Aug 2021; status: completed.
02
Drugs
lzm012
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20212135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212135.